Business Context and Reporting Period
Company: Actuate Therapeutics, Inc. (ACTU)
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2025
Reporting Period: Event-based report regarding a Key Opinion Leader (KOL) event held on May 31, 2025.
The Company hosted a KOL event to review topline Phase 2 data (Actuate-1801 Part 3B) for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for the first-line treatment of metastatic pancreatic cancer (mPDAC). The data was presented at the American Society of Clinical Oncology 2025 Annual Meeting (ASCO 2025).
Key Financial Metrics
This filing is a current report regarding a clinical data event and does not contain specific financial statements, revenue figures, profit margins, or cash flow data for the period.
Liquidity and Capital Resources: The filing explicitly states that the Company's financial condition raises substantial doubt as to its ability to continue as a going concern. The Company requires additional capital to finance operations beyond the second quarter of fiscal year 2025.
Material Changes
No material changes to financial position or operations are reported in this specific filing. The primary material event is the dissemination of clinical trial data and the subsequent discussion with Key Opinion Leaders.
Guidance, Outlook, Risks, and Contingencies
- Clinical Outlook: The Company is advancing the development of elraglusib based on Phase 2 data. Future plans depend on regulatory submissions and potential approval.
- Capital Risk: There is a significant risk that the Company may not obtain necessary capital in the near term on acceptable terms. Failure to secure funding could force the Company to delay, limit, reduce, or terminate development programs and commercialization efforts.
- Development Risks: Clinical trials involve uncertain timelines and outcomes. Preliminary data is subject to change. Regulatory approval is not guaranteed, and the drug may face safety risks or adverse events.
- Forward-Looking Statements: The filing contains numerous forward-looking statements regarding clinical trials, development plans, and industry conditions, which are subject to substantial risks and uncertainties.
Investor Verification Checklist
- Verify the specific topline data results for the Actuate-1801 Part 3B trial by reviewing the ASCO 2025 presentation slides and the KOL event transcript (Exhibit 99.1).
- Review the most recent Form 10-Q (filed May 15, 2025) and Form 10-K (filed March 13, 2025) for detailed financial statements and the full "Risk Factors" section.
- Assess the Company's current cash runway and any announced plans for capital raising to address the "substantial doubt" regarding going concern status.
- Monitor regulatory communications with the FDA and EMA regarding the next steps for elraglusib development.